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Prostate cancer (PCa) is the most frequently diagnosed type of cancer in developed countries.The decisive method of diagnosis is
based on the results of biopsies, morphologically evaluated to determine the presence or absence of cancer. Although this approach
leads to a confident diagnosis in most cases, it can be improved by using the molecular markers present in the tissue. Both miRNAs
and proteins are considered excellent candidates for biomarkers in formalin-fixed paraffin-embedded (FFPE) tissues, due to their
stability over long periods of time. In the last few years, a concerted effort has been made to develop the necessary tools for their
reliable measurement in these types of samples. Furthermore, the use of these kinds of markers may also help in establishing tumor
grade and aggressiveness, as well as predicting the possible outcomes in each particular case for the different treatments available.
This would aid clinicians in the decision-making process. In this review, we attempt to summarize and discuss the potential use of
microRNA and protein profiles in FFPE tissue samples as markers to better predict PCa diagnosis, progression, and response to
therapy.
1. Introduction
Prostate cancer (PCa) is the most commonly diagnosed
cancer and the second leading cause of cancer death among
European and American men [1]. The current screening
method to diagnose PCa is based on ameasurement of serum
prostate specific antigen (PSA) levels and a digital rectal
examination (DRE), while a decisive diagnosis is based on
the results of transrectal, ultrasound-guided prostate biopsies
(PBs).
The introduction of the serum PSA test in the late 1980s
has led to an increase in the detection of new PCa cases [2].
However, serumPSAhas somewell-recognized limitations; it
lacks diagnostic specificity and prognostic value, and it leads
to a high rate of false positives [3]. This lack of specificity
is associated with an increased percentage of negative PB
and the overdiagnosis of many indolent tumors, resulting
in the overtreatment of patients. Consequently, there exists
urgent need to find more effective and specific PCa detection
markers.
The management of diagnosed PCa is crucially depen-
dent on the presentation of the disease [4]. By nature, PCa
progresses slowly and can be treated effectively with early
detection by radical prostatectomy (RP); however, patients
diagnosed with high risk PCa or metastatic disease have a
50% risk of disease progression 5 years after surgery [5]. For
this reason, these patients are provided with closer follow-up
and more intensive treatment by adjuvant therapy to avoid
local and distant disease, usually radiation therapy (RT) and
androgen deprivation therapy (ADT) [6]. To help clinicians
choose the best treatment approach for each particular case,
it is critical to identifymarkers that distinguish indolent cases
of PCa from those that will progress and metastasize.
In the past few years, thanks to current advancements
in proteomics, RNA and DNA microarrays, immunohisto-
chemical (IHC) staining, and other biotechnologies, new
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approaches have been applied to identify and validate more
accurate diagnostic and prognostic biomarkers in tissue
samples [7].
2. Biomarker Discovery in FFPE Tissue
Although fresh-frozen (FF) tissue remains the gold stan-
dard for extraction and large-scale profiling in genomic
and proteomic studies, analyzing molecules in formalin-
fixed paraffin-embedded (FFPE) tissues is gaining increased
interest. This interest is primarily driven by the fact that
the process of creating FFPE tissue is the most common
technique used by clinical and/or research pathologists for
tissue processing, evaluation, diagnostics, immunoanalysis,
preservation, and archiving.These archived FFPE tissuesmay
provide wealth of information when used in retrospective
molecular studies that focus on molecular profiling and
biomarker research [8]. It is true that the quantity and
quality of proteins, nucleic acids, and metabolites obtained
from FFPE tissues are inferior to the extraction efficiency
obtained from FF tissues [8, 9]. However, the use of FFPE
samples in molecular expression analysis studies presents
some great advantages. For example, these types of samples
are available and readily accessible in vast quantities.The cost
associated with their storage is low, as well, and the significant
association between pathological and clinical annotations
makes FFPE tissue an attractive specimen for biomarker
discovery. Nevertheless, when working with nucleic acids,
FFPE samples present some drawbacks as RNA and DNA
can be degraded and modified by the fixation process and,
independently, degraded with time.
In the late 1990s, tissue microarray (TMA) technology
revolutionized the investigation of potential prognostic and
predictive biomarkers [10, 11]. TMAs are commonly used
to study tissue morphology, the expression of proteins or
genes, and chromosomal aberrations using IHC and in situ
hybridization (ISH) [11]. The combination of TMAs and
clinically annotated samples is useful when studying panels of
biomarkers under identical experimental conditions, as well
as in the development of prognostic or predictive models for
patient outcome [12]. Despite these considerable advantages,
the conventional construction of TMAs is often meticu-
lous, laborious, and time consuming. Recently, Zlobec et al.
[11] proposed the term, next-generation tissue microarrays
(ngTMAs), to define a combination of cutting-edge digital
pathology, automated TMAs, and histopathological exper-
tise, which would ultimately benefit the further optimization
of biomarker research.
The purpose of this review is to examine the potential use
of previously described, small noncoding RNAs,microRNAs,
and protein profiles as markers that may help predict PCa
diagnosis, progression, and response to therapy in prostate
FFPE specimens. To date, only a few of these markers have
achieved widespread clinical use.
2.1. MicroRNAs as Biomarkers in Prostate FFPE Samples. In
recent years, evidence has accumulated showing that small
noncoding RNAs are used in a conserved manner to regulate
key developmental events. At least four classes of regula-
tory, small noncoding RNAs have been described, including
microRNAs (miRNAs), short interfering RNAs (siRNA),
repeat-associated small interfering RNAs (rasiRNAs), and
piwi-interacting RNAs (piRNAs) [13]. Among these small
RNAs, the miRNAs, which are the most phylogenetically
conserved, posttranscriptionally regulate the genes involved
in several physiological and pathological processes [14–16].
Therefore, their aberrant expression results in a variety of
pathological events, such as cancer [17, 18]. Generally, the
importance of miRNAs in cancer is emphasized by the fact
that around 50% of all miRNA genes are positioned in so-
called fragile sites, genomic regions that are associated with
repeated changes that occur in cancer [18, 19].Moreover,miR-
NAs are attractive candidates as multifunctional regulators
of disease progression, because one miRNA can regulate an
entire set of genes [20]. It is believed that miRNAs regulate
about 30%of all protein-coding human genes [21–23]. Finally,
several miRNAs and their targets have been found to be
aberrantly expressed in PCa [18, 24–26]. For that reason,
certain miRNAs are now considered valuable biomarkers for
diagnosis, prognosis, and the classification of PCa [27, 28].
Furthermore, miRNAs present several advantageous fea-
tures that make them a source of potential cancer biomarkers
in FFPE tissues. First, unlike other nucleic acids, miRNAs
are potentially more robust. Due to their small size and
protection by the RISC complex, which makes them resistant
to endogenous RNase activity, they are less affected by FFPE-
dependent degradation [29–32]. Second, their expression
levels can be measured reliably in FFPE tissue samples,
and only minute quantities of RNA are needed to establish
their expression using reliable, quantitative PCR amplifi-
cation strategies [33]. Third, miRNA expression profiles
are not dependent on the preservation of the specimen’s
architecture and cellular arrangement or the degree of cellular
degeneration [29]. Finally, a good correlation between the
expression profiles of FF and FFPE samples with miRNAs
and messenger RNAs (mRNAs) has been observed and
reported in liver [34], glioblastoma [35], and PCa specimens
[36]. Therefore, the expression profiling of miRNAs is an
accurate and robust method for the molecular analysis of
archived clinical specimens, which potentially extends the
use of miRNAs as new diagnostic, prognostic, and treat-
ment response biomarkers [30]. Currently, high-throughput
screening methods, such as microarrays, can be applied to
detect miRNAs in prostate FFPE tissues; however, quantita-
tive real-time reverse-transcription PCR (qRT-PCR) is still
one of the most common high sensitivity and specificity
methods used to detect low miRNA levels [37].
In recent years, specific miRNA signatures for PCa have
been described in several studies [27, 28, 38–44], suggesting
that miRNAs or miRNA profiles can be used as diagnostic
and prognostic markers for this disease [45]. These markers
exhibit distinct abilities to detect PCa and to predict disease
course. Some of them are listed in Table 1 and discussed
below.
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Table 1: miRNAs as PCa biomarkers in FFPE tissue.
miRNA Clinical significance References
Let-7 family Diagnosis, prognosis (↓) [45, 52]
miR-17 Diagnosis, prognosis (↓) [154, 155]
miR-19a Diagnosis [156]
miR-20a/b Diagnosis [154]
miR-21 Prognosis (↑), treatment outcome [157]
miR-25 Diagnosis [156]
miR-26a Diagnosis (↓) [21]
miR-29a Diagnosis (↓) [21, 158]
miR-29b Diagnosis (↓) [159]
miR-31-5p Diagnosis (↓) [66]
miR-30d Diagnosis (↑) [21]
miR-34a Diagnosis (↓) [21, 160]




miR-125b Diagnosis (↑) [25]
miR-126 Diagnosis (↓) [21]
miR-132 Prognosis (↓), treatment outcome [161]
miR-141 Diagnosis [154]
miR-143 Diagnosis, prognosis (↓) [43, 51, 156]
miR-145 Diagnosis, prognosis (↓) [43, 49–51, 154, 162]
miR-146a/b-5p Diagnosis, prognosis (↓) [163]
miR-183-96-182 cluster Diagnosis, prognosis [56, 59, 66, 154, 164]
miR-187 Diagnosis [156]
miR-195 Diagnosis (↓) [21]
miR-200a Treatment outcome [56]
miR-203 Diagnosis, prognosis (↓) [164]
miR-214 Diagnosis [154]
miR-221 Diagnosis, prognosis (↓), treatment outcome [55, 154]
miR-222 Diagnosis [154]
miR-342-3p Diagnosis (↑) [21]
miR-375 Diagnosis (↑) [43, 154]
miR-519d Prognosis (↑), treatment outcome [67]
miR-616 Diagnosis (↑) [165]
miR-622 Diagnosis (↑) [21]
miR-647 Prognosis (↓), treatment outcome [67]
miR-720 Diagnosis [154]
miR-768-3p Diagnosis [154]
miR-1256 Diagnosis (↓) [158]
Arrows indicate the sense of deregulation: (↑): upregulation; (↓): downregulation in PCa versus normal tissues or low risk versus high risk PCa.
The downregulation of miRNAs is the most frequently
observed phenomenon in cancer, suggesting that they func-
tion as tumor suppressor genes [46]. Loss of mir-145 expres-
sion has been reported in many human cancers [47, 48],
including PCa [49]. The downregulation of miR-145 has
been associated with an aggressive phenotype and poor
prognosis in PCa [50]. Peng et al. [51] reported that in FFPE
specimens the downregulation of miR-143 and miR-145 was
negatively correlated to bone metastasis, Gleason score, and
the level of free PSA in primary PCa. Recently, Suh et al.
[49] documented that the downregulation of miR-145 in PCa
could play a role in cancer initiation, and that the mechanism
for its regulation is mediated by DNA methylation and p53
mutation pathways (a protein marker discussed later in this
review).
Some of the most frequently mentioned miRNAs that
appear downregulated in PCa aremembers of the let-7 family
[45].This family appears to play a key role in the recurrence
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and progression of PCa by maintaining and regulating the
molecular features of cancer stem cells (CSCs) or cancer
stem-like cells [52]. Loss of the let-7 family has been found
in human PCa FFPE tissue specimens, especially in higher
Gleason grade tumors, and it has been strongly linked to the
acquisition of epithelial to mesenchymal transition (EMT)
phenotype [52] and to the negative regulation of RAS protein
[53]. These data suggest that inducing the re-expression
of miRNAs from the let-7 family could represent a new
therapeutic approach for aggressive PCa. A very recent report
[45] identified let-7b as an independent prognostic marker
for biochemical recurrence (BCR) and clinical failure in high-
risk PCa. Furthermore, alterations in the expression profile of
miR-let7c, miR-100, andmiR-218 have been described during
the progression from localized to metastatic PCa [46, 54].
MiR-221 is also a strongly downregulated miRNA in
PCa, as clearly confirmed by several miRNA expression
studies of PCa [28, 39, 40, 55]. Spahn et al. [55] identified a
miRNA profile, (including miR-221, which has been related
to metastasis) comparing the miRNA expression patterns
in primary carcinoma and lymph node metastatic tissue.
Moreover, the downregulation of miR-221 was associated
with clinicopathological parameters, including Gleason score
and clinical recurrence. These results suggest that miR-221
could be a novel prognostic indicator in high risk PCa, and it
could be clinically useful for advising additional therapeutic
strategies to PCa patients.
MiR-200a, a member of the miR-200 family, has been
implicated in the regulation of EMT and postulated to be
hijacked by cancer cells during tumormetastasis [56]. Barron
et al. [56] showed downregulation of miR-200a in PCa tissue
from men who relapsed compared to those who did not.
Moreover, they also observed reduced expression of the other
two miRNAs in the miR-200a cluster (miR-200b and miR-
429), suggesting that those miRNAs are jointly repressed
in patients suffering from relapsing disease. Although miR-
200a did not demonstrate adequate sensitivity or specificity
to serve as a reliable relapse predictor, surely it could be
considered a valuable addition to a panel of biomarkers.These
findings are supported by other recent studies, which link
miR-200 family members to PCa progression [52].
On the other hand, overexpressedmiRNAs in cancer have
occasionally been observed [38, 57]. These may function as
oncogenes and promote cancer development by negatively
regulating tumor suppressor genes and/or genes that control
cell differentiation or apoptosis.
The overexpression of miR-183, miR-96 and miR-182,
individually or as a cluster, has been reported in cancer
[58], including PCa [59, 60]. In particular, mir-182-5p has
been described as an oncogene in several cancers [61–64]. Its
expression was found to be significantly higher in PCa tissues
compared to normal prostate tissues [59, 60, 65], and it has
been associated with shorter overall survival in PCa patients.
Recently, Tsuchiyama et al. [66] demonstrated that in FFPE
tissue samples, the expressions of miR-182-5p, as well as mir-
31-5p andmir-205-5p, were significantly higher in high grade
tumors compared to those of intermediate grade.This would
suggest that miR-182-5p is a useful marker for high grade
PCa.
Long et al. [67], analyzing the expression profiles of 70
archived FFPE tumor specimens, showed that miR-519d and
miR-647 could serve as biomarkers to discriminate between
patients with and without BCR following RP. MiR-519d was
positively associated with the risk of BCR, while miR-647
presented a negative association.
2.2. Protein Biomarkers in Prostate FFPE Samples. The diag-
nosis of PCa in histopathological specimens is based mainly
on a combination of architectural and cellular atypia, and
in a vast majority of cases, a confident diagnosis can be
made based on morphology alone. However, in some cases,
the morphological findings are insufficient for a conclusive
diagnosis, either because the atypia is too mild or the atypical
focus is too small.The diagnostic accuracy of a morphology-
based diagnosis can be improved in some cases by IHC that
uses one or several biomarkers, either on consecutive sections
or by the use of stained marker cocktails [68].
The detection of protein biomarkers by IHC presents
multiple advantages, due to their high stability in FFPE
tissues compared to other molecules. Multiple reports have
shown that proteins and even protein modifications, such
as phosphorylations, are maintained and can be determined
years later by IHC [69]. In the last two decades, the ability to
detect antigens in tissue sections has improved dramatically,
mainly by countering the deleterious effects of formaldehyde
with antigen retrieval and increasing the sensitivity of the
detection systems [70]. From a clinical perspective, the
IHC method correlates molecular detail to histopathological
changes found in patient-derived tissues. Consequently, IHC
is an excellent, simple, and effective technique for the detec-
tion of molecular biomarkers in FFPE samples. Currently,
the IHC method is considered one of the pillars of modern
diagnostic pathology and a fundamental research tool in both
pathology and translational research laboratories [71]. Some
of the proteinmarkers used for PCa diagnosis, prognosis, and
response to therapy are listed in Table 2.
It is well known that despite the fact that it is neither organ
nor cancer specific, PSA is the most important, accurate,
and clinically useful biochemical marker in the prostate
[72–74]. As proved using IHC techniques, PSA expression
is localized to the differentiated, secretory columnar cells
of the glandular epithelium [75]. The apical portion of
the epithelial cell cytoplasm shows more intense staining
than the lower part, whereas the basal cells, transitional
epithelium, or stromal cells do not express PSA. The PSA
protein is strongly expressed, both in normal and neoplastic
prostatic tissue; however, as evidenced by IHC staining, it
is expressed less in cancer than in benign epithelium, and
its expression decreases with the decreasing differentiation
of PCa [76, 77]. Although IHC detection of PSA is still
widely used to identify metastatic prostatic adenocarcinoma,
PSA may not be expressed in some poorly differentiated
prostatic carcinomas [78–80]. Its immunoreactivity has also
been found in some nonprostatic tissues [81–83], making it
useless, in such cases, for confirming prostatic origin.
Recently, novel marker proteins that are preferentially
expressed in prostate tissue have been identified. Prostein
BioMed Research International 5
Table 2: Proteins as PCa biomarkers in FFPE tissue.
Protein Description Clinical significance References
PSA Prostate-specific antigen Diagnosis (prostatic metastasis) [84]
P501S Prostein Diagnosis (prostatic metastasis) [84, 85]
PSCA Prostate stem cell antigen Diagnosis (incl. metastasis), prognosis(↑) [86–88]
AMACR/P504S #-methylacyl-CoA racemase Diagnosis (↑) [89–91, 94, 110, 114]
HMWCK High-molecular-weight cytokeratin Diagnosis (↓) [101, 103–105, 110]
ANXA3 Annexin A3 Prognosis (↓) [166]
CgA Chromogranin A Prognosis (↑), treatment outcome [144–147]
OPN Osteopontin Prognosis (↑) [167]
ZAG Zinc-alpha 2-glycoprotein Prognosis (↓) [168, 169]
PSMA Prostate-specific membrane antigen Diagnosis, prognosis (↑) [170, 171]
GOLPH2 Golgi phosphoprotein 2 Diagnosis (↑) [99, 100]
GST-pi Glutathione-S-transferase-pi Diagnosis (↓) [172]
HPN Hepsin Diagnosis (↑) [173, 174]
Maspin Maspin protein/Serpin B5 Diagnosis (↓, aberrant nucleardistribution) [172, 175, 176]
MMP9 Matrix metallopeptidase 9 Prognosis (↑) [177, 178]
PDEF/hPSE Prostate-derived Ets transcription factor Diagnosis, prognosis (↓) [177, 179, 180]
SPINK1/TATI Serine protease inhibitor Kazal-type1/Tumor-associated trypsin inhibitor Diagnosis, prognosis (↑) [181, 182]
Ki67 Antigen KI-67 Prognosis (↑), treatment outcome [121, 122, 183]
B7-H3 and B7x B7 family members Prognosis (↑) [131, 133]
p53 Cellular tumor antigen p53 Diagnosis (↑), treatment outcome [134, 135]
p27 Protein p27 Prognosis (↓) [184, 185]
p16 Protein p16 Prognosis (↓), treatment outcome [186, 187]
uPA Urokinase-type plasminogen activator Prognosis (↑), treatment outcome [188, 189]
MCT2 Monocarboxylate transporter 2 Diagnosis (↑) [190]
AR Androgen receptor Prognosis (↓), treatment outcome [119, 191]
PTEN Phosphatase and tensin homologue Prognosis (↓), treatment outcome [115, 117–119, 183]
MSMB/PSP94 $-Microseminoprotein/prostate secretory protein 94 Prognosis (↑) [192]
EZH2 Histone-lysine N-methyltransferase Prognosis (↑) [185, 193]
HSP27 Heat shock 27 kDa protein Prognosis (↑) [194, 195]
ErbB2/HER2 Receptor tyrosine-protein kinase erbB-2 Prognosis (↑) [196, 197]
NKX3.1 Homeobox protein Nkx-3.1 Diagnosis (prostatic metastasis) [198]
c-Myc Myc protooncogene protein Prognosis (↑), treatment outcome [183, 185]
BIRC5 Baculoviral IAP repeat-containing protein 5/Survivin Prognosis (↓) [199, 200]
KLK4 Kallikrein-4 Prognosis (↓) [201]
TERT Telomerase reverse transcriptase Prognosis (↑), treatment outcome [202, 203]
CRISP3 Cysteine-rich secretory protein 3 Diagnosis, prognosis (↑), treatmentoutcome [95, 204]
BCL2 Apoptosis regulator Bcl-2 Prognosis (↑), treatment outcome [139–141]
COX2 Prostaglandin G/H synthase 2 Treatment outcome [124, 128, 130]
VEGF-A Vascular endothelial growth factor A Prognosis (↑), treatment outcome [205, 206]
HIF-1# Hypoxia-inducible factor 1-alpha Treatment outcome [207, 208]
Arrows indicate the sense of deregulation: (↑): upregulation; (↓): downregulation in PCa versus normal tissues or low risk versus high risk PCa.
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(P501S), a prostate-specific marker that is expressed in the
cytoplasm of benign and malignant prostatic glandular cells,
is one of them. Owing to its high specificity and the fact that
a large majority of metastatic prostatic adenocarcinomas are
prostein positive (99%), the combined use of P501S with PSA
could be a good marker for demonstrating prostatic origin in
metastatic PCa [84, 85].
Several studies using FFPE samples have shown that
prostate stem cell antigen (PSCA), a prostate-specific gene,
is expressed in most PCa specimens. Its levels are positively
correlated with Gleason grade, tumor stage, progression to
androgen-independence, and BCR and have also been found
to be particularly elevated in bone metastasis [86–88]. All
these data suggest that PSCA may be useful in prognosis and
may be a promising molecular target in the diagnosis and
treatment of patients with metastatic PCa. Another marker
shown to be specifically increased in PCa epithelia, compared
to benign epithelia, is #-methylacyl-CoA racemase (AMACR
or P504S) [89–91]. P504S is a PCa-specific gene that encodes
a protein involved in the beta-oxidation of branched chain
fatty acids. It is a sensitive and specific marker for prostatic
carcinoma in FFPE tissues [92, 93]. Both high grade and
low-grade PCa show strong cytoplasmic staining; however, a
significant decrease in AMACR protein expression has been
observed in cases of metastatic hormone-refractory disease
compared with clinically localized PCa samples [94].
A useful IHC biomarker for PCa may be cysteine-rich
secretory protein 3 (CRISP-3), also known as the specific
granule protein of 28 kDa (SGP28). CRISP-3 was found to be
associated with high Gleason grade with elevated intensity,
and it was also overexpressed in high-grade prostatic intraep-
ithelial neoplasia (HG-PIN), which indicates that CRISP-
3 could be a marker for early cancer development [95,
96]. In addition, patients positive for CRISP-3 have smaller
recurrence-free probabilities after RP [97]. Another protein-
based candidate for PCa diagnosis is Golgimembrane protein
1 (GOLM1, also known as GP73 and GOLPH2), a trans-
membrane protein expressed in the epithelial cells of many
human tissues [98]. Several studies have recently reported
the upregulation of this protein in malignant prostate tissue,
suggesting GOLM1 as an additional ancillary positive marker
for the tissue-based diagnosis of PCa [99, 100]. On the
other hand, PCa tissues, even those of high grade, only
rarely express high-molecular-weight cytokeratin (HMWCK,
sometimes also referred to as 34$E12, an anti-cytokeratin
antibody, clone-specific for high-molecular-weight cytok-
eratins (cytokeratins 1, 5, 10, and 14)). That makes this
marker a useful adjunct in the diagnosis of PCa [101, 102].
HMWCK immunoreactivity in benign glands is localized
to the cytoplasm of basal cells and is negative in PCa. It
is a particularly sensitive marker for the differentiation of
PCa from high grade invasive urothelial carcinoma, where
it can be detected by IHC [103–105]. Even though HMWCK
labeling of PCa cells is uncommon, p63 has been reported to
be evenmore specific thanHMWCKas amarker for the basal
cell nuclei of benign glands and with less tumor cell labeling
[106].
The use of cocktails that include different antibodies as
a routine test overcomes the problems of studying small
lesions in prostate needle biopsies with multiple IHC stains
[107, 108]. For this reason, many studies have focused on
attempting new combinations of markers that could improve
the diagnostic process. For example, the overexpression of
AMACR, in combination with the absence of basal cell
markers, such as HMWCK or p63, is typical of classic acinar
prostatic adenocarcinoma. Its detection has been shown to
be of great value in combatting morphologically suspicious
cases, as well as significantly increasing diagnostic accuracy
in PCa [91, 109–112]. Furthermore, several studies have com-
pared the usefulness of a three-marker cocktail of antibodies
for detecting PCa. These cocktails incorporated AMACR
(positive in malignant glands), p63 (nuclear staining in basal
cells of nonmalignant glands), and HMWCK (cytoplasmic
staining in basal cells of nonmalignant glands), alongwith the
traditional two-marker cocktail. These studies all concluded
that adding an extra basal cell marker to the traditional two-
antibody cocktail significantly improved specificity for the
detection of PCa in limited needle biopsy material [107, 113,
114].
Phosphatase and tensin homolog on chromosome 10
(PTEN) has been described as one of the most frequently
lost tumor suppressor genes in human cancers. Its expres-
sion is lost in more than two thirds of patients with
advanced/aggressive PCa. Moreover, genomic and proteomic
PTEN loss has been associated with tumor progression and
poor prognosis in PCa [115–117]. In patients with clinically
localized PCa, who were treated by RP, decreased PTEN
expression has also been associated with an increased risk
of recurrence and decreased time to metastasis [115, 118].
Choucair et al. [119] examined the deletion status of PTEN
and the androgen receptor (AR) expression levels in FFPE
PCa samples and found that PTEN genomic deletion predicts
PCa recurrence. It was also associatedwith lowARexpression
and transcriptional activity.
Expression of the human Ki67 protein is known to be
strictly associatedwith cell proliferation.The fraction ofKi67-
positive tumor cells (the Ki67 labeling index, Ki67 LI) is
often in correlation with the clinical course of the disease,
including cases of PCa, where cell proliferation evaluated by
Ki-67 increases from localized PCa to metastasis [54, 120].
A high Ki67 LI is independently associated with seminal
vesicle infiltration and postoperative Gleason score. More
importantly, the Ki67 LI can predict biochemical recurrence,
particularly in the subgroup of patients with only a small
amount of tumor in the biopsy. The Ki67 LI could also
be a valid predictor of recurrence-free survival after radical
prostatectomy [121, 122].
Cyclooxygenase-2 (COX-2) is also highly expressed in a
number of human cancers and cancer cell lines, including
PCa [123]. The potential roles of COX-2 in tumor related
processes, such as tumorigenesis, angiogenesis [123–125],
and radiation treatment resistance, make this an attractive
biomarker candidate and potential therapeutic target [126–
129]. Increased COX-2 expression is associated with bio-
chemical failure and distant metastasis; therefore, it could be
useful in identifying patients who require more aggressive
therapy [130].
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Recently discovered members of the B7-CD28 family, B7-
H3, and B7x, were evaluated by IHC on pathological spec-
imens from clinically localized PCa patients treated by RP
[131, 132].These studies concluded that B7-H3 was uniformly
and aberrantly expressed in PCa and correlated to the worst
clinical outcomes of this disease [131].Therefore, B7-H3 could
represent an independent predictor of cancer progression
following surgery. Moreover, B7-H3 may encompass a novel
diagnostic and potentially therapeutic target for the clinical
management of PCa [131]. Another IHC study performed
on tissue microarray sections using anti-B7-H3 and anti-B7x
corroborated that these proteins were abundantly expressed
in PCa and were associated with the spread of disease and
poor outcome [133].
It has been suggested that p53 accumulation or TP53
mutation could be used as both prognostic and predictive
biomarkers. This is the most commonly mutated gene in
human cancer and has been associated with poor prognosis
in multiple and distinct types of cancer, including PCa [124,
134]. Abnormal p53 expression is a significant prognostic
factor for patients with PCa, who have undergone short-term
ADT and/or RT. It has also been suggested that long-term
ADTmay significantly improve the cause-specific survival for
thosewith abnormal p53 [135]. Another biomarker associated
with higher Gleason scores and lower biochemical-free sur-
vival in patients with advanced PCa undergoingADTorRT is
the gene product of the apoptosis regulator Bcl-2.The relative
amounts of Bcl-2 and/or BAX, a proapoptotic protein from
the same family, have been shown to correlate with tumor
aggressiveness and radiation resistance in PCa [124, 136–138].
These data suggest that Bcl-2 expression could be used to
inform the choice of ADT or RT dosage in individual patients
[139–141].
The RI-alpha regulatory subunit of protein kinase A type
1 (PKA) is associated with active cell growth and neoplastic
transformation. Its overexpression has been found to be pre-
dictive of outcome in PCa patients treated with RT and short-
term ADT and is considered a potentially useful biomarker
for identifying high risk PCa patients [142]. Another study
from the same group showed that its overexpression was
associated with an increased risk of failure after ADT and RT,
suggesting that novel strategies may be needed for patients
with tumors presenting high PKA levels [124, 143].
Most of the conventional prostate adenocarcinomas dis-
play focal neuroendocrine (NE) differentiation at diagnosis.
The NE phenotype is emerging as an important factor in
the evolution of PCa, since it seems to be implicated in the
development of resistance to ADT [144]. Chromogranin A
(CgA) appears to be the most sensitive marker, and it is the
most frequently used marker for detecting the NE phenotype
by IHC [145]. It has a strong association with pathological
tumor stage, since its expression levels are higher in poorly
differentiated carcinomas. It has also been identified as an
additional prognostic marker after RP [146, 147].
3. Conclusions
For a long time, PSA screening for PCa has been contro-
versial. Although the PSA test is simple and safe and has
an acceptable sensitivity and specificity, the implementation
of PSA screening for PCa costs nearly double is associated
with a high risk of overdiagnosis, and as a consequence
presents the inevitable side effects that arise fromunnecessary
treatment [148]. The current method of definitive diagnosis
for PCa typically relies on the morphological findings in the
biopsied tissue, which, even for an experienced pathologist,
can be difficult to classify. This method could be improved
by using one or several molecular markers, which would
help the pathologist to make the final diagnostic decision
and differentiate between clinically significant and clinically
insignificant disease. Thus, novel markers are required to
improve the specificity of PCa diagnosis and to fully char-
acterize the heterogeneity of prostate tumor phenotypes.
These markers will more accurately assess the diagnosis and
prognosis of patients with PCa [149].This strategy would play
an important role in achieving better patient management in
the clinical practice. It would also assure a decrease in the
number of repeat biopsies and faster identification of those
patients who require more aggressive therapy. It is evident
that there exists urgent need to identify better biomarkers
for PCa presence, progression, and response to treatment,
in order to avoid unnecessary overtreatment and accurately
predict disease outcome.
Recently, several attempts have been made to identify
novel biomarkers for PCa, though the results were largely
inconclusive [21]. However, several studies mentioned in
this review have demonstrated that it is possible to find
differentially expressed miRNAs and proteins that can dis-
tinguish between normal and malignant prostate tissues and
can be used to classify and correctly diagnose even poorly
differentiated tumor samples.Thus, bothmiRNA and protein
expression profiles have potential as tools for the diagnosis
and prognosis of cancer.
New technologies will be of great assistance in the appli-
cation of these promising biomarkers to routine practice. An
important challenge in cancer diagnostics will be to assay
multiple parameters in a single slide when tissue quantities
are limited. The development of multiplexed assays that
maximize the yield of information from a small biopsy will
help meet a critical challenge to current biomarker research.
Accordingly, the implementation of ISH, in combination
with IHC for the detection of clinically important miRNAs
and protein markers in fixed specimens, now provides a
fluorescence-based multicolor ISH/IHC assay. This assay
is rapid, sensitive, and compatible with current automated
clinical IHC assays and provides spatial characterization
of miRNA expression [150, 151]. Thanks to this combined
ISH/IHC assay, miRNA and protein biomarkers can now
be used together in detecting, classifying, diagnosing, prog-
nosing, and treating cancer. For multiplexing protein panels
Matrix-assisted laser desorption ionization (MALDI) imag-
ing mass spectrometry (IMS) appears as a powerful tool
for the generation of multidimensional spatial expression
maps of biomolecules directly from a FFPE tissue section.
From a clinical proteomics perspective, this method corre-
lates molecular detail to histopathological changes found in
patient-derived tissues. Targeted IMS, by the incorporation of
laser-reactive molecular tags onto antibodies, aptamers, and
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other affinitymolecules, enables analysis of specificmolecules
or a class of molecules. The integration of MALDI-IMS
methods into existing clinical pathology laboratory practices
could prove beneficial to diagnostics [152].
New strategies for the detection of PCa in biopsies
material are also being developed. For example, a recent
study described a new type of bioactive membrane vesicle
(with the proposed name “large oncosomes”) which can
originate from tumor cells and is related to high Gleason
grade and metastatic disease.They suggest that the detection
of these pathological features could be adapted for routine
histopathological analysis [153].
In this review, we have attempted to provide examples
of potential miRNA and protein markers that have been
discovered in prostate FFPE tissues, which may be of clin-
ical benefit in PCa detection, prognosis, and/or prediction.
Clearly, it would be beneficial to concentrate future efforts on
the discovery and further study of themolecularmechanisms
and regulatory pathways associated with PCa. This will
help to improve the design and target selection of new
therapeutic strategies. In summary, the development of novel
and clinically relevant biomarkers in FFPE tissues for PCa
diagnosis, prognosis, and prediction could contribute to the
optimal identification and treatment of this disease.
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